Harvard Medical School investigators at Massachusetts General Hospital have identified a potential mechanism behind the resistance that inevitably develops to cancer treatments which combine chemotherapy and antiangiogenic drugs.
In a paper published in Science Translational Medicine, the researchers report that treating metastatic colorectal cancer with antiangiogenesis drugs such as bevacizumab (Avastin) significantly increases several components of the extracellular matrix and also adds stiffness within liver metastases in both patients and mouse models.
“Systemic chemotherapy is a cornerstone of therapy for metastatic colorectal cancer, and the introduction of antiangiogenic drugs like bevacizumab has extended patients’ survival, although the tumors ultimately progress,” said Dai Fukumura, HMS associate professor of radiation oncology at Mass General and one of the study’s co-senior authors. “Understanding how tumors become resistant to treatment could help us develop novel strategies to overcome those mechanisms of resistance.”
Antiangiogenesis drugs were originally thought to improve cancer treatment by cutting off a tumor’s blood supply. However, Rakesh Jain, the A. Werk Cook Professor of Radiation Oncology (Tumor Biology) at HMS and Mass General and co-senior author of the current study, developed a different hypothesis for how they worked.
When given in judicious doses, Jain reasoned, the drugs acted by normalizing the abnormal vasculature within a tumor, thus improving the delivery of chemotherapy drugs and response to radiation treatment. This has been supported by many studies.
Another factor that can impede drug delivery within tumors is a buildup of compressive forces that squeeze blood vessels shut. In addition to the pressure exerted by proliferating tumor cells, the extracellular matrix surrounding the tumor cells also contributes to these forces.
Some recent studies have found that the hypoxia—reduction in oxygen supply—induced by antiangiogenic therapy increases the expression of collagen, a major component of the extracellular matrix, in primary tumors. The Mass General team set out to investigate whether other matrix components, specifically hyaluronic acid (HA) and sulfated glycosaminoglycans (sGAGs), were also affected by antiangiogenic therapy and if they contributed to treatment resistance.
The research team first studied samples of liver metastases from patients with colorectal cancer and found the HA expression was increased within tumors, compared with unaffected liver tissue, and was even higher in metastases from patients who had received antiangiogenic therapy. In two mouse models of metastatic colorectal cancer, they found that antiangiogenic treatment increased compressive forces within liver metastases by stiffening tissues.
Expression of both HA and sGAG was significantly higher after antiangiogenic treatment in the mouse models. In addition, antiangiogenic therapy appeared to cause an influx of suppressor immune cells that would reduce any immune response against the tumor.
Analysis of metastatic tissue from the mouse models revealed increased hypoxia and decreased density of microvessels after antiangiogenic therapy, which was followed by measurable increases in HA and sGAG. Inducing hypoxia in human liver stellate cells, the primary source of extracellular matrix, led to a more than fourfold increase in the expression of HA.
Adding an enzyme that targets HA to antiangiogenesis treatment in one of the mouse models caused a 74 percent reduction in HA levels and prolonged the animals’ survival, compared with combination chemotherapy and antiangiogenesis alone.
“Although various mechanisms of resistance to antiangiogenesis therapy have been suggested, our study is the first to propose a role for the extracellular matrix and alterations in the mechanical properties of tumors,” said Fukumura. “In addition to showing for the first time that antiangiogenesis therapy changes these properties within tumors, we also found that the hypoxia induced by extracellular matrix abnormalities attracts the immunosuppressive cells that help the tumor evade a systemic immune cell attack.”
The authors note that their findings in animal models need to be validated in controlled clinical trials in human patients.
“If these trials are successful, ‘normalizing’ the matrix may improve treatment outcomes in multiple cancers, since these tumors harbor an excessive quantity of abnormal extracellular matrix,” said Jain.
Filed Under: Drug Discovery
